Armed with $1M MDA grant, ARMGO to develop drug

04/18/2013 | Genetic Engineering & Biotechnology News

The Muscular Dystrophy Association's MDA Venture Philanthropy unit awarded a $1 million grant to ARMGO Pharma for preclinical work on a small-molecule Rycal drug for Duchenne muscular dystrophy. The treatment targets leaks in an intracellular calcium channel that contribute to loss of muscle strength and function in muscular dystrophy.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC